The Chinese government recently submitted a second draft of the Drug Administration Law of the People’s Republic of China to the Standing Committee of the National People’s Congress of China for deliberation. Life sciences partner Katherine Wang (Shanghai) authored an article published by Asia-Pacific Biotech News on June 12 that discusses the major changes.
Ms. Wang notes that while the proposed draft codifies many reform initiatives that accelerate market access of innovative drugs, it also signals aggressive post-approval enforcement and severe sanctions.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.